STOCKHOLM, Dec. 1, 2017 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) today announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by…
